Acrux Limited has entered into an exclusive commercialisation agreement with Padagis in the United States for one of the products in the Acrux portfolio. Padagis will be responsible for the commercialisation of the product, including sales, distribution and coordination of manufacturing. Padagis and Acrux will share the profits generated from the sales of the product.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.081 AUD | +3.85% | +19.12% | +84.09% |
03/04 | Acrux, TruPharma Launch Dapsone 5% Gel in US | MT |
29/02 | Transcript : Acrux Limited, H1 2024 Earnings Call, Feb 29, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+84.09% | 15.07M | |
+15.91% | 42.02B | |
+22.40% | 21.66B | |
+18.48% | 15.09B | |
+16.12% | 14.21B | |
+45.12% | 12.37B | |
-0.05% | 6.79B | |
-9.58% | 6.59B | |
-8.87% | 5.73B | |
+14.18% | 5.56B |
- Stock Market
- Equities
- ACR Stock
- News Acrux Limited
- Acrux Limited Announces Commercial Agreement with Padagis